A Phase 4 interventional study of Motivation and lifestyle intervention in Ischemic Stroke, Cognitive Decline and Dementia, sponsored by Danube University Krems. Completed at 5 sites in Austria. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-01-13.
Sponsored by Danube University Krems · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Ischemic Stroke with a site in Austria — 12 open to participants now, 15 under way, 1 of them phase 3. Ischemic Stroke · Austria.
Among the 49 studies in Ischemic Stroke with a site in Austria, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2010, is one of 5 in phase 4, and was the 15th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →12 of the 49 studies in Ischemic Stroke with a site in Austria are open now. Recruiting first, the newest first:
Sigmund Freud PrivatUniversitat · Sites in Austria
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Austria, Germany, Switzerland
Ages 18+
MED-EL Elektromedizinische Geräte GesmbH · Sites in Austria
Ages 18–99
VASCage GmbH · Sites in Austria
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Austria, Belgium, Canada and 9 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 10 · Phase 4 5
First in 2000; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 447 across the 34 interventional studies, 1,000 across the 12 observational. Of the 32 that completed or were terminated, 12 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 49 have an industry lead sponsor. The 10 most frequent:
Danube University Krems is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Danube University Krems has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
4 of the studies in Ischemic Stroke with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07511868VASCage GmbHDigital Application for Stroke Health | 2026-12-31 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT04582825VASCage GmbHStroke-Card Registry | 2027-03-31 |
| NCT07299981Sigmund Freud PrivatUniversitatQuantitative Net Water Uptake as a Predictor of Functional Outcomes After Intravenous Thrombolysis in Acute Ischemic Stroke International Multicenter Observational Retrospective Study | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies in Ischemic Stroke with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim of this randomized controlled study is to test if intensive polyintervention therapy including life style modifications targeting at reduction of modifiable risk factors of stroke can reduce the risk of post-stroke cognitive decline compared to a group of patients receiving standard care.
Stroke is the second most frequent cause of death and cognitive deficits including dementia occur frequently following a stroke. The frequency of cognitive disturbances has been reported up to 30% and thus occurs three times more frequent than recurrent stroke (10%). Major attempts have been made to prevent the occurrence of new strokes by means of effective strategies including preventive drugs. In contrast, hardly any studies have been performed addressing the prevention of deteriorating cognitive function following a stroke. In spite of this high prevalence therapeutic possibilities are extremely limited. It must be expected that cognitive deficits become even a more frequent disability following stroke. This is caused by the increased aging of the population leading to further increase of incidence, furthermore that more people survive their acute stroke due to increased possibilities of acute treatment, and that frequent risk factors (e.g. hypertension, diabetes) are increasingly controlled, thus leading to less severe strokes with less severe and permanent motor deficits, but an increase of potentially disabling cognitive disturbances. The aim of this randomized controlled study is to test an intensive multiple intervention therapy for the first time in stroke and to add life style modifications targeting modifiable risk factors for cognitive deterioration.
It is hypothesized that the risk of post-stroke cognitive decline can be significantly reduced compared to a control group with standard care when using polyintervention. These interventions will focus on nutrition, exercise, cognitive and social activity and monitoring and management of metabolic and vascular risk factors. Regular contacts with the subjects shall increase motivation and adherence to the study protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
Behavioral: Motivation and lifestyle intervention
Standard stroke care
Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
Number of persons having cognitively declined at 24 months
Cognitive decline is defined as a significant decline in the composite scores of at least 2 of 5 neuropsychologically tested domains (speed of mental processing, executive functions, working memory, memory, spatial constructive functions). The alpha level for the decision is 0.05.
Time frame: 24 months after randomization
Cognitive decline measured on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog) at 24 months
Difference between the measures at baseline and at 24 months on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog).
Time frame: 24 months after randomization
Number of persons having cognitively declined 12 months after randomization
Cognitive decline is defined as a significant decline in the composite scores of at least 2 of 5 neuropsychologically tested domains (speed of mental processing, executive functions, working memory, memory, spatial constructive functions). The alpha level for the decision is 0.05.
Time frame: 12 months after randomization
Cognitive decline on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog) at 12 months
Difference between the measures at baseline and at 12 months on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog).
Time frame: 12 months after randomization
Cognitive impairment on the Mini-Mental-State-Examination (MMSE) scale at 12 months
Time frame: 12 months after randomization
Cognitive impairment on the Mini-Mental-State-Examination (MMSE) scale at 24 months
Time frame: 24 months after randomization
Change in cognitive abilities measured by composite scores for each of 5 cognitive domains
For each of the five cognitive domains (executive functions, working memory, general memory, speed of cognitive processing, visual spatial ability) standardized composite scores are calculated from the differences between baseline and 12 months in individual neuropsychological test results.
Time frame: 12 months after randomization
Composite outcome for vascular events
vascular events include recurrent stroke, ACS, bypass surgery, PTA and vascular death
Time frame: 24 months after randomization
Neurological status on the National Institute of Health Stroke Scale (NIHSS) score
Time frame: 12 months after randomization
Functional status on the modified Rankin Scale
Time frame: 12 months after randomization
Activities of daily living on Barthel Index
Time frame: 12 months after randomization
Quality of life on the EQ-5D
Time frame: 12 months after randomization
Depression on the Center for Epidemiologic Studies Depression Scale (CESD)
Time frame: 12 months after randomization
All cause mortality
Time frame: 24 months after randomization
Change in cognitive abilities measured by composite scores for each of 5 cognitive domains
For each of the five cognitive domains (executive functions, working memory, general memory, speed of cognitive processing, visual spatial ability) standardized composite scores are calculated from the differences between baseline and 24 months in individual neuropsychological test results.
Time frame: 24 months after randomization
Neurological status on the National Institute of Health Stroke Scale (NIHSS)score
Time frame: 24 months after randomization
Functional status on the modified Rankin Scale
Time frame: 24 months after randomization
Activities of daily living on Barthel Index
Time frame: 24 months after randomization
Quality of life on the EQ-5D
Time frame: 24 months after randomization
Depression on the Center for Epidemiologic Studies Depression Scale (CESD)
Time frame: 24 months after randomization
The record gives a start of Jun 2010, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Danube University Krems